Mobilization of stem cell: past, present and future

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article reflects the main stages of development of high-dose chemotherapy with autologous stem cell as an effective method of treatment of various hematological, oncological and hereditary diseases. It describes the development of the research beginning with the discovery of the stem cells by A.A Maksimov to the contemporary ways to elaborate them into blood; it reflects the basic mechanisms of action of different groups of drugs on complex biochemical cascades close interaction with hematopoietic cells of the bone marrow microenvironment, which, in turn, determines their further destiny and lead to a loss of hematopoietic stem cells in peripheral blood. However, in spite of the current approaches to improve ways of harvesting stem cell, there is a certain percentage of patients in whom it is impossible to collect adequate for quick recovery of hematopoiesis after high-dose chemotherapy number of cells. This percentage will vary according to various literature sources, 5 to 40 %. Therefore, the development and application of new drugs, growth factors and cytokines, which would overcome the problem of poor mobilization is an important issue in modern medicine. The article presents data on the use of a new mobilizing agent plerixafor, the use of which in practice improves the successful mobilization of 40 %. The study of its combined action of various growth factors, including pegylated filgrastim, is a promising direction, because can be a good option for patients with poor mobilization activity for which the previous regimen mobilization proved ineffective. The research of plerixafor interacting with various growth factors including pegylated filgrastim is considered to be the most promising direction. This method is believed to help patients with low mobilizing activity where all other means have failed to improve it.

Full Text

Restricted Access

About the authors

Margarita S Motalkina

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
Postgraduate Student, Department of Oncology, Hematology and Bone Marrow Transplantation

Svetlana A Kulyova

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
MD, PhD, Dr Med Sci, Professor, Head, Department of Children`s Chemoterapy and Combined Modality Therapy

Sergei M Alekseev

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
MD, PhD, Deputy Director

Ilia S Zuzgin

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
Associate Professor, Head, Department of Oncology, Hematology and Bone Marrow Transplantation

Larisa V Filatova

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
MD, PhD, Dr Med Sci, Researcher, Department of Oncology, Hematology and Bone Marrow Transplantation

Albina S Zhabina

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
MD, PhD, Researcher, Department of Oncology, Hematology and Bone Marrow Transplantation

Anna S Artemyeva

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
Associate Professor, Department of Educational-Methodical Work

Alla A Rjazankina

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
Associate Professor, Department of Educational-Methodical Work

Tatiana Yu Semiglazova

N.N. Petrov Oncology Research Institute

Email: Kulevadoc@yandex.ru
Dr Sci, Project Leader, Scientific Department of Innovative Methods of Therapy and Rehabilitation

References

  1. Волкова М.А. Клиническая онкогематология. М.: Медицина, 2007. [Volkova MA. Klinicheskaya onkogematologiya. Moscow: Meditsina; 2007. (In Russ).]
  2. Покровская О.С. Механизм действия и клиническая эффективность антагониста хемокинового рецептора CXCR4 плериксафора при мобилизации гемопоэтических стволовых клеток // Клиническая онкогематология. - 2012. - Т. 4. - С. 371-9. [Pokrovskaya OS. Mekhanizm deystviya i klinicheskaya effektivnost’ antagonista khemokinovogo retseptora CXCR4 pleriksafora pri mobilizatsii gemopoeticheskikh stvolovykh kletok. Klinicheskaya onkogematologiya. 2012;4:371-9. (In Russ).]
  3. Avecilla ST, Hattori K, Heissig B. Chemokine mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10(1):64-71. doi: 10.1038/nm973.
  4. Bakany SM, Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients. J Bone Marrow Transplant. 2012;47:1154-63. doi: 10.1038/bmt.2011.170.
  5. Calandra G, McCarty J, McGuirk J. AMD3100 plus G CSF can successfully mobilize CD34+-cells from non Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41(4):331-8. doi: 10.1038/sj.bmt.1705908.
  6. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med. 2006;354:1813-26. doi: 10.1056/NEJMra052638.
  7. Costa LJ, Kramer C, Hogan KR. Pegfilgrastim versus filgrastim based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x.
  8. Di Persio JF, Micallef IN, Stiff PJ. Phase III prospective randomized double blind placebo controlled trial of plerixafor plus granulocyte colony stimulating factor compared with placebo plus granulocyte colony stimulating factor for autologous stem cell mobilization and transplantation for patients with non Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209.
  9. Di Persio JF, Stadtmauer EA, Nademanee A. Plerixafor and G CSF versus placebo and G CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-6.
  10. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005;114(4):198-205. doi: 10.1159/000088410.
  11. Greenbaum AM, Link DC. Mechanisms of G CSF mediated hematopoietic stem and progenitor mobilization. Leukemia. 2011;25(2):211-7. doi: 10.1038/leu.2010.248.
  12. Kim MG, Han N, Lee EK, Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta analysis. Bone Marrow Transplant. 2015;10:1038.
  13. Korbling M, Przepiorka D, Gajewski J. With first successful allogeneic transplantations of apheresis derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood. 1995;86:1235-8.
  14. Krause DS, Fackler MJ, Civin CI. CD34: structure, biology, and clinical utility. Blood. 1996;87(1):1-13.
  15. Linker C, Anderlini P, Herzig R. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant. 2003;9(6):405-13. doi: 10.1016/S1083-8791(03)00101-0.
  16. Martino M, Laszlo D, Lanza F. Long active granulocyte colony stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. Expert Opin Biol Ther. 2014;14(6):757-72. doi: 10.1517/14712598.2014.895809.
  17. Maximow AA. Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Säugetiere. Folia Haematol. 1909;8:125-34.
  18. Moskowitz CH, Glassman JR, Wuest D. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res. 1998;4:311-6.
  19. Pelus LM. Peripheral blood stem cell mobilization:new regimens, new cells, where do we stand. Curr Opin Hematol. 2008;15:285-92. doi: 10.1097/MOH.0b013e328302f43a.
  20. Siena S, Schiavo R, Pedrazzoli P. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18:1360-77.
  21. Wilson A, Trumpp A. Bone marrow haematopoietic stem cell niches. Nat Rev Immunol. 2006;6(2):93-106. doi: 10.1038/nri1779.
  22. Wuchter P, Ran D, Bruckner T. Poor Mobilization of Hematopoietic Stem Cells Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biol Blood Marrow Transplant. 2010;16:490-9. doi: 10.1016/j.bbmt.2009.11.012.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Motalkina M.S., Kulyova S.A., Alekseev S.M., Zuzgin I.S., Filatova L.V., Zhabina A.S., Artemyeva A.S., Rjazankina A.A., Semiglazova T.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies